Sellas, Life

Sellas Life Sciences: A Survival Win and a $172.5 Million Equity Raise, Side by Side

Published on 11/21/2026 at 15:21 | Editorial boerse-global.de
Sellas reported a Phase 3 survival win for galinpepimut-S and a $172.5M discounted share sale in the same week; the stock fell 8.1% Friday.
Sellas Life Sciences Illustration mit AI erstellt.

Two announcements landed in the same week for Sellas Life Sciences, and the market treated them very differently. On one side sits a Phase 3 readout that hit its primary endpoint in acute myeloid leukemia. On the other sits a discounted share sale that pushed the stock down 8.1% on Friday. Both are facts about the same company; neither cancels the other out.

The clinical result

Sellas reported on November 17 that galinpepimut-S met the primary endpoint of overall survival in the Phase 3 REGAL trial. The company put the reduction in mortality risk at 41% versus the best available treatment. It quantified the effect with a hazard ratio of 0.59 and a p-value of 0.035.

Median overall survival came in at 24.0 months on galinpepimut-S against 14.7 months for the best available treatment. The hazard ratio and the median comparison describe different facets of the same dataset and should not be conflated. On the strength of these figures, Sellas intends to meet with the US Food and Drug Administration and press ahead with preparations for a marketing application.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

The financing that followed

The company also completed a public offering in the same week. It sold 13,269,231 shares at $13.00 apiece, generating gross proceeds of $172.5 million before costs. The underwriters exercised their overallotment option in full, which is what brought the total to roughly 13.3 million shares. Fees, commissions and other expenses still come out of that headline number, so gross proceeds and net cash received are not the same figure.

The placement's timing matters for reading the balance sheet. When Sellas published its quarterly results on November 12, it reported cash and cash equivalents of $134.7 million as of September 30 — a snapshot taken before the capital raise closed.

Reading the two together

A trial that reaches its primary endpoint and a share sale that dilutes existing holders can both shape how a stock is valued at the same moment. The clinical win is not diminished by the new shares, and the terms of the raise are not erased by good data. Investors weighing Sellas need the survival numbers and the offering price in the same frame, because each answers a question the other leaves open.

Ad

Sellas Life Sciences Stock: New Analysis - 21 November

Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Sellas Life Sciences analysis...

Disclaimer...
en | US81642T2096 | SELLAS | boerse | 70542781 |